Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial von Zalcman, Gérard, Prof, Mazieres, Julien, Prof, Margery, Jacques, MD, Greillier, Laurent, MD, Audigier-Valette, Clarisse, MD, Moro-Sibilot, Denis, Prof, Molinier, Olivier, MD, Corre, Romain, MD, Monnet, Isabelle, MD, Gounant, Valérie, MD, Rivière, Frédéric, MD, Janicot, Henri, MD, Gervais, Radj, MD, Locher, Chrystèle, MD, Milleron, Bernard, MD, Tran, Quan, MSc, Lebitasy, Marie-Paule, MD, Morin, Franck, MSc, Creveuil, Christian, PhD, Parienti, Jean-Jacques, Prof, Scherpereel, Arnaud, Prof

Volltext

PARAMOUNT: Final Overall Survival Results of the Phase III Study of Maintenance Pemetrexed Versus Placebo Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for A... von PAZ-ARES, Luis G, DE MARINIS, Filippo, CORRAL, Jesús, MELEMED, Symantha, JOHN, William, CHOUAKI, Nadia, ZIMMERMANN, Annamaria H, VISSEREN-GRUL, Carla, GRIDELLI, Cesare, DEDIU, Mircea, THOMAS, Michael, PUJOL, Jean-Louis, BIDOLI, Paolo, MOLINIER, Olivier, TARINI PRASAD SAHOO, LAACK, Eckart, RECK, Martin

Volltext

Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study von Cappuzzo, Federico, Dr, Ciuleanu, Tudor, MD, Stelmakh, Lilia, MD, Cicenas, Saulius, Prof, Szczésna, Aleksandra, MD, Juhász, Erzsébet, MD, Esteban, Emilio, MD, Molinier, Olivier, MD, Brugger, Wolfram, MD, Melezínek, Ivan, MUDr CSc, Klingelschmitt, Gaëlle, MSc, Klughammer, Barbara, PhD, Giaccone, Giuseppe, Prof

Volltext

Efficacy of Immune Checkpoint Inhibitors in Lung Sarcomatoid Carcinoma von Domblides, Charlotte, Leroy, Karen, Monnet, Isabelle, Mazières, Julien, Barlesi, Fabrice, Gounant, Valérie, Baldacci, Simon, Mennecier, Bertrand, Toffart, Anne-Claire, Audigier-Valette, Clarisse, Doucet, Ludovic, Giroux-Leprieur, Etienne, Guisier, Florian, Ricordel, Charles, Molinier, Olivier, Perol, Maurice, Pichon, Eric, Robinet, Gilles, Templement-Grangerat, Dorine, Ruppert, Anne-Marie, Rabbe, Nathalie, Antoine, Martine, Wislez, Marie

Volltext

Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squam... von Paz-Ares, Luis, Dr, de Marinis, Filippo, MD, Dediu, Mircea, MD, Thomas, Michael, Prof, Pujol, Jean-Louis, Prof, Bidoli, Paolo, MD, Molinier, Olivier, MD, Sahoo, Tarini Prasad, MD, Laack, Eckart, Prof, Reck, Martin, MD, Corral, Jesús, MD, Melemed, Symantha, PhD, John, William, MD, Chouaki, Nadia, MD, Zimmermann, Annamaria H, MS, Visseren-Grul, Carla, MD, Gridelli, Cesare, MD

Volltext

Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial von Quoix, Elisabeth, Prof, Zalcman, Gérard, Prof, Oster, Jean-Philippe, MD, Westeel, Virginie, Prof, Pichon, Eric, MD, Lavolé, Armelle, MD, Dauba, Jérôme, MD, Debieuvre, Didier, MD, Souquet, Pierre-Jean, MD, Bigay-Game, Laurence, MD, Dansin, Eric, MD, Poudenx, Michel, MD, Molinier, Olivier, MD, Vaylet, Fabien, MD, Moro-Sibilot, Denis, Prof, Herman, Dominique, MD, Bennouna, Jaafar, MD, Tredaniel, Jean, Prof, Ducoloné, Alain, MD, Lebitasy, Marie-Paule, MD, Baudrin, Laurence, MSc, Laporte, Silvy, PhD, Milleron, Bernard, MD

Volltext

Neoadjuvant durvalumab for resectable non-small-cell lung cancer (NSCLC): results from a multicenter study (IFCT-1601 IONESCO) von Wislez, Marie, Mazieres, Julien, Lavole, Armelle, Zalcman, Gérard, Carre, Olivier, Egenod, Thomas, Caliandro, Raffaele, Dubos-Arvis, Catherine, Jeannin, Gaelle, Molinier, Olivier, Massiani, Marie-Ange, Langlais, Alexandra, Morin, Franck, Le Pimpec Barthes, Francoise, Brouchet, Laurent, Assouad, Jalal, Milleron, Bernard, Damotte, Diane, Antoine, Martine, Westeel, Virginie

Volltext

Pathologic Complete Response to Preoperative Chemotherapy Predicts Cure in Early-Stage Non–Small-Cell Lung Cancer: Combined Analysis of Two IFCT Randomized Trials von Mouillet, Guillaume, Monnet, Elisabeth, Milleron, Bernard, Puyraveau, Marc, Quoix, Elisabeth, David, Philippe, Ducoloné, Alain, Molinier, Olivier, Zalcman, Gérard, Depierre, Alain, Westeel, Virginie

Volltext

Major changes in lung cancer over the last ten years in France: The KBP-CPHG studies von Locher, Chrystèle, Debieuvre, Didier, Coëtmeur, Daniel, Goupil, François, Molinier, Olivier, Collon, Thierry, Dayen, Charles, Le Treut, Jacques, Asselain, Bernard, Martin, Francis, Blanchon, François, Grivaux, Michel

Volltext

MST1/Hippo promoter gene methylation predicts poor survival in patients with malignant pleural mesothelioma in the IFCT-GFPC-0701 MAPS Phase 3 trial von Maille, Elodie, Brosseau, Solenn, Hanoux, Vincent, Creveuil, Christian, Danel, Claire, Bergot, Emmanuel, Scherpereel, Arnaud, Mazières, Julien, Margery, Jacques, Greillier, Laurent, Audigier-Valette, Clarisse, Moro-Sibilot, Denis, Molinier, Olivier, Corre, Romain, Monnet, Isabelle, Gounant, Valérie, Langlais, Alexandra, Morin, Franck, Levallet, Guénaëlle, Zalcman, Gérard

Volltext

Does Very Poor Performance Status Systematically Preclude Single Agent Anti-PD-1 Immunotherapy? A Multicenter Study of 35 Consecutive Patients von Gounant, Valerie, Duruisseaux, Michael, Soussi, Ghassen, Van Hulst, Sylvie, Bylicki, Olivier, Cadranel, Jacques, Wislez, Marie, Tredaniel, Jean, Spano, Jean-Philippe, Helissey, Carole, Chouaid, Christos, Molinier, Olivier, Dhalluin, Xavier, Doucet, Ludovic, Hureaux, Jose, Cazes, Aurelie, Zalcman, Gerard

Volltext

Second- or third-line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: Results of the IFCT-1501 MAPS2 randomized phase II trial von Scherpereel, Arnaud, Mazieres, Julien, Greillier, Laurent, Dô, Pascal, Bylicki, Olivier, Monnet, Isabelle, Corre, Romain, Audigier-Valette, Clarisse, Locatelli-Sanchez, Myriam, Molinier, Olivier, Thiberville, Luc, Urban, Thierry, Ligeza-poisson, Catherine, Planchard, David, Amour, Elodie, Morin, Franck, Moro-Sibilot, Denis, Zalcman, Gerard

Volltext

Second- or third-line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: Results of the IFCT-1501 MAPS2 randomized phase II trial von Scherpereel, Arnaud, Mazieres, Julien, Greillier, Laurent, Dô, Pascal, Bylicki, Olivier, Monnet, Isabelle, Corre, Romain, Audigier-Valette, Clarisse, Locatelli-Sanchez, Myriam, Molinier, Olivier, Thiberville, Luc, Urban, Thierry, Ligeza-poisson, Catherine, Planchard, David, Amour, Elodie, Morin, Franck, Moro-Sibilot, Denis, Zalcman, Gerard

Volltext

P1.07-012 Efficacy of Immune Checkpoint Inhibitors in Large Cell Neuroendocrine Lung Cancer: Results from a French Retrospective Cohort von Levra, Matteo Giaj, Mazieres, Julien, Valette, Clarisse Audigier, Molinier, Olivier, Planchard, David, Frappat, Violaine, Ferrer, Leonie, Toffart, Anne Claire, Moro-Sibilot, Denis

Volltext

Model of uncertainty for the variability of water microbiological enumeration in a proficiency testing scheme von Molinier, Olivier, Guarini, Philippe

Volltext

Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 t... von Scherpereel, Arnaud, Mazieres, Julien, Greillier, Laurent, Lantuejoul, Sylvie, Dô, Pascal, Bylicki, Olivier, Monnet, Isabelle, Corre, Romain, Audigier-Valette, Clarisse, Locatelli-Sanchez, Myriam, Molinier, Olivier, Guisier, Florian, Urban, Thierry, Ligeza-Poisson, Catherine, Planchard, David, Amour, Elodie, Morin, Franck, Moro-Sibilot, Denis, Zalcman, Gérard, DEBIEUVRE, Didier, HIRET, Sandrine, CADRANEL, Jacques, FRABOULET-MOREAU, Séverine, CARMIER, Delphine

Volltext

Development and Validation of a Simplified Prognostic Score in SCLC von Negre, Elodie, Coffy, Amandine, Langlais, Alexandra, Daures, Jean-Pierre, Lavole, Armelle, Quoix, Elisabeth, Molinier, Olivier, Greillier, Laurent, Audigier-Valette, Clarisse, Moro-Sibilot, Denis, Westeel, Virginie, Morin, Franck, Roch, Benoît, Pujol, Jean-Louis

Volltext

Randomized Trial Comparing a Web-Mediated Follow-up With Routine Surveillance in Lung Cancer Patients von Denis, Fabrice, Lethrosne, Claire, Pourel, Nicolas, Molinier, Olivier, Pointreau, Yoann, Domont, Julien, Bourgeois, Hugues, Senellart, Hélène, Trémolières, Pierre, Lizée, Thibaut, Bennouna, Jaafar, Urban, Thierry, El Khouri, Claude, Charron, Alexandre, Septans, Anne-Lise, Balavoine, Magali, Landry, Sébastien, Solal-Céligny, Philippe, Letellier, Christophe

Volltext

Association Between Nocturnal Hypoxemia and Cancer Incidence in Patients Investigated for OSA Data From a Large Multicenter French Cohort von Justeau, Gregoire, Gerves-Pinquie, Chloe, Le Vaillant, Marc, Trzepizur, Wojciech, Meslier, Nicole, Goupil, Francois, Pigeanne, Thierry, Launois, Sandrine, Leclair-Visonneau, Laurene, Masson, Philippe, Bizieux-Thaminy, Acya, Humeau, Marie-Pierre, Gosselin, Christelle, Blanchard, Margaux, Urban, Thierry, Gagnadoux, Frederic

Volltext

First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer von Shaw, Alice T, Bauer, Todd M, de Marinis, Filippo, Felip, Enriqueta, Goto, Yasushi, Liu, Geoffrey, Mazieres, Julien, Kim, Dong-Wan, Mok, Tony, Polli, Anna, Thurm, Holger, Calella, Anna M, Peltz, Gerson, Solomon, Benjamin J

Volltext